Recent Posts
- And that’s a wrap 2023! Christmas with IR Department
- This is what the ASX and investors expect for gender diversity on your board
- 5 key lessons any company can take away from our foundational ESG report
- What small caps can take away from Amazon’s move to write emissions data into its supplier standards
- How Australian small caps are likely to be impacted by the new ISSB sustainability disclosure standards
Archives
Servatus launches new trial into the effects of live biotherapeutics on insomnia
Servatus launches new trial into the effects of live biotherapeutics on insomnia, we talk to CEO Dr Wayne Finlayson to discuss this exciting initiative.
Servatus CEO Dr Wayne Finlayson discusses the company’s new human clinical trial into the link between the gut microbiome and sleep by treating patients who suffer from insomnia with live biotherapeutics
